A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Trial Number
EudraCT: 2019-001655-39Contact Person
Status
Closed to Recruitment
Disease Site
Cervical
Lead Cooperative Group
Participating Groups
GOG-F
AGO-AUST
CEEGOG
GEICO
NCRI
AGO
CTI
GINECO
NSGO-CTU
DGOG
MITO